Aarti PharmalabsNSE:AARTIPHARM +0.70%55 Days Payable is 107.86 as of Mar. 2026, which is 3% below its 10-year median of 111.22. GuruFocus rates NSE:AARTIPHARM with a GF Score™ of 55/100 and a GF Value™ of ₹636.14 (Fairly Valued). The stock has 3 warning signs investors should review. Among 920 Drug Manufacturers companies, Aarti Pharmalabs ranks better than 69.57% on this metric.
The historical rank and industry rank for Aarti Pharmalabs's Days Payable or its related term are showing as below:
NSE:AARTIPHARM'
s Days Payable Range Over the Past 10 Years
Min: 44.52 Med: 111.22 Max: 133.87
Current: 130.84
During the past 6 years, Aarti Pharmalabs's highest Days Payable was 133.87. The lowest was 44.52. And the median was 111.22.
NSE:AARTIPHARM's Days Payable is ranked better than 69.57% of 920
companies
in the Drug Manufacturers industry
Industry Median: 90.835
vs NSE:AARTIPHARM: 130.84
Aarti Pharmalabs's Days Payable
increased
from Mar. 2025 (97.64) to Mar. 2026 (107.86).
It may suggest that Aarti Pharmalabsdelayed paying its suppliers.
Aarti Pharmalabs Days Payable Related Terms
Aarti Pharmalabs Days Payable Historical Data
* Premium members only.
The historical data trend for Aarti Pharmalabs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AARTIPHARM vs ZTS, UTHR: Days Payable Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Aarti Pharmalabs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Days Payable distribution charts can be found below:
* The bar in red indicates where Aarti Pharmalabs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Aarti Pharmalabs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Aarti Pharmalabs (NSE:AARTIPHARM) has a Days Payable of 107.86 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aarti Pharmalabs and its competitors. This is near median its historical median of 111.22. Over the past decade, Aarti Pharmalabs' Days Payable has ranged from 44.52 to 133.87. According to the industry distribution chart, Aarti Pharmalabs ranks #280 out of 920 companies in the Drug Manufacturers industry, placing it in the top 30.4%.
Is Aarti Pharmalabs' Days Payable too high?
Aarti Pharmalabs' current Days Payable of 107.86 is near median its 10-year median of 111.22. Over the past 10 years, this metric has ranged from a low of 44.52 to a high of 133.87. The Drug Manufacturers industry median Days Payable is 90.84. Aarti Pharmalabs' value of 107.86 is 18.7% above this industry median. Based on the distribution chart, Aarti Pharmalabs ranks #280 out of 920 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Aarti Pharmalabs has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Aarti Pharmalabs' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Aarti Pharmalabs ranks #280 out of 920 companies for Days Payable. This puts Aarti Pharmalabs in the upper half of its industry. The industry median Days Payable is 90.84. Aarti Pharmalabs' value of 107.86 is 18.7% above this benchmark. Historically, Aarti Pharmalabs' own Days Payable has ranged from 44.52 to 133.87 over the past decade. While the company's 10-year median is 111.22 vs. the industry median of 90.84, Aarti Pharmalabs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.84, based on 920 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Aarti Pharmalabs's current Days Payable of 107.86 is 18.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Aarti Pharmalabs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Aarti Pharmalabs's current Days Payable is 107.86, which is near median its own 10-year median of 111.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Pharmalabs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Pharmalabs (NSE:AARTIPHARM) is currently considered Fairly Valued. The stock's GF Value™ is ₹636.14, compared to a current price of ₹680.05 — trading 6.9% above its estimated fair value. The current Days Payable is 107.86, which is near median its 10-year median of 111.22 and 18.7% above the Drug Manufacturers industry median of 90.84. Aarti Pharmalabs' overall GF Score™ is 55/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Aarti Pharmalabs (NSE:AARTIPHARM), the current Days Payable is 107.86 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?
Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued.
The current stock price of ₹680.05 is trading 6.9% above its estimated GF Value™ of ₹636.14.
GuruFocus considers Aarti Pharmalabs to be Fairly Valued.
Key valuation signals for NSE:AARTIPHARM:
Days Payable: 107.86 (near median its 10-year median of 111.22)
GF Value™: ₹636.14 vs. price of ₹680.05 (6.9% above fair value)
Industry Position: 18.7% above the Drug Manufacturers median (#280 of 920)
No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
55GF Score
Get the complete analysis for NSE:AARTIPHARM
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AARTIPHARM has been successfully added to your 
